GILD Jun 2024 110.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 02:10PM EDT. Market open.
| Previous Close | 0.0700 |
| Open | 0.1700 |
| Bid | 0.0000 |
| Ask | 1.4400 |
| Strike | 110.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 0.0700 - 0.1700 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 26 |
- Thomson Reuters StreetEvents
Q1 2024 Gilead Sciences Inc Earnings Call
Q1 2024 Gilead Sciences Inc Earnings Call
Business WireFDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
FOSTER CITY, Calif., April 26, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy of
- GuruFocus.com
Gilead Sciences Inc (GILD) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...
Explore Gilead's latest financial performance and strategic directions, including updates on HIV, oncology, and liver disease segments.
© 2024 Yahoo. All rights reserved.